Literature DB >> 16508626

Radiofrequency ablation of liver metastases from colorectal carcinoma.

Eric C Feliberti1, Lawrence D Wagman.   

Abstract

BACKGROUND: Most patients with colorectal carcinoma will develop liver metastases. Radiofrequency ablation (RFA) has been utilized in metastatic CRC to help improve the survival gap between resectable and unresectable tumor.
METHODS: The current use of RFA in selected patient populations is reviewed.
RESULTS: RFA provides a survival benefit in patients with unresectable hepatic metastases from CRC compared with chemotherapy alone. It offers effective local tumor destruction in appropriately selected lesions and minimizes the morbidity and mortality of an open resection. Common complications are abdominal bleeding (1.6%), abdominal infection (1.1%), and injury to the biliary tree (1.0%). Mortality ranges from 0% to 0.5%.
CONCLUSIONS: Trials are underway to compare chemotherapy plus local ablation to chemotherapy alone. RFA is a tool that should be utilized by experienced individuals to achieve optimal oncologic outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 16508626     DOI: 10.1177/107327480601300107

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  11 in total

1.  CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

Review 2.  Thermal Ablation in the Management of Colorectal Cancer Patients with Oligometastatic Liver Disease.

Authors:  Elena Nadia Petre; Constantinos Sofocleous
Journal:  Visc Med       Date:  2017-02-03

3.  Totally laparoscopic strategies for the management of colorectal cancer with synchronous liver metastasis.

Authors:  Francesco M Polignano; Aaron J Quyn; Pandanaboyana Sanjay; Nikola A Henderson; Iain S Tait
Journal:  Surg Endosc       Date:  2012-03-22       Impact factor: 4.584

4.  Hepatectomy is superior to thermal ablation for patients with a solitary colorectal liver metastasis.

Authors:  Suzanne Claire Schiffman; Matthew Bower; Russell E Brown; Robert C G Martin; Kelly M McMasters; Charles R Scoggins
Journal:  J Gastrointest Surg       Date:  2010-09-22       Impact factor: 3.452

5.  Colorectal liver metastases; the current scenario.

Authors:  Samir Pathak; Graeme J Poston
Journal:  Indian J Surg Oncol       Date:  2011-04-19

6.  Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.

Authors:  Hua-Jung Li; Maaike Everts; Masato Yamamoto; David T Curiel; Harvey R Herschman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases.

Authors:  Kyung Ho Kim; Yong Sik Yoon; Chang Sik Yu; Tae Won Kim; Hye Jin Kim; Pyo Nyun Kim; Hyun Kwon Ha; Jin Cheon Kim
Journal:  J Korean Surg Soc       Date:  2011-07-11

8.  Radiofrequency ablation with systemic chemotherapy in the treatment of colorectal cancer liver metastasis: a 10-year single-center study.

Authors:  Shuangyan Ou; Ruocai Xu; Ke Li; Yong Chen; Yi Kong; Hanchun Liu; Jianliang Li; Yongzhong Ouyang; Xiaoping Yu
Journal:  Cancer Manag Res       Date:  2018-10-31       Impact factor: 3.989

Review 9.  Radiofrequency ablation of pulmonary tumours: current status.

Authors:  Karin Steinke
Journal:  Cancer Imaging       Date:  2008-03-03       Impact factor: 3.909

10.  The role of radiofrequency ablation for treatment of metachronous isolated hepatic metastasis from colorectal cancer.

Authors:  Byoung Chul Lee; Hyun Gu Lee; In Ja Park; So Yeon Kim; Ki-Hun Kim; Jae Hoon Lee; Chan Wook Kim; Jong Lyul Lee; Yong Sik Yoon; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.